By contrast, the risk of acneiform dermatitis was markedly greater with Cetuximab, reaching 12-fold that of Nivolumab (ROR = 12.31), closely paralleling the high incidence of rash (≥80%) observed in the EXTREME trial, thereby confirming the skin-specific toxicity characteristic of EGFR inhibition. Here, EGFR is linked to acneiform dermatitis.